Clinical effect of Nicorandil on patients with acute ST-segment elevation myocardial infarction after percutaneous coronary intervention

Abstract

Objective To investigate the effects of nicorandil (NIC) on patients with acute anterior myocardial infarction (AMI). Methods A retrospective study was performed on 121 cases of patients with acute anterior wall ST segment elevation myocardial infarction and receive emergency percutaneous coronary intervention (PCI), 101 cases of male, female 20 cases, aged (61.35±3.93) years old, ranging from 46 to 77 years, by using the method to stochastic indicator were randomly divided into conventional treatment group (n=61) and nicorandil group (n=60). Conventional treatment group receiving coronary atherosclerotic heart disease in patients with secondary prevention medicine, nicorandil group in the conventional treatment group on the basis of preoperative via coronary artery injection, can to 4 mg, postoperative oral 5 mg, three times a day, for six months, observed in two groups of patients in slow blood flow and the occurrence of no reflow, myocardial infarction, thrombolysis trial (TIMI) flow grade, serum myocardial hypersensitive troponin level and the occurrence of postoperative hospitalization for heart failure and arrhythmia, the occurrence of cardiac events (including recurrent myocardial infarction, congestive heart failure, rehospitalization, and all-cause death) in the two groups was observed 6 months after the operation.The occurrence of angina pectoris in the two groups during the treatment period was recorded. Results The 24 hours after emergency PCI, the level of hypersensitive troponin in nicorandil group [(4 407±809) pg/ml]was lower than that in the conventional group [(7 456±1 028) pg/ml], with statistically significant difference (P<0.05). The incidence of heart failure [6.6% (4/61)]in the nicorandil group was lower than that in the conventional group [20.0% (12/60)], and the incidence of arrhythmia [9.8% (6/61)]was lower than that in the conventional group [23.3% (14/60)], with statistically significant differences (P<0.05). The recurrence rate of angina pectoris in the nicorandil group [6.6% (4/61)]was lower than that in the conventional group [23.3% (14/60)], and the difference was statistically significant (P<0.05). Conclusion Continuous nicorandil therapy can reduce myocardial injury in patients with acute ST-segment elevation myocardial infarction, improve short-term therapeutic effect of acute ST-segment elevation myocardial infarction, and improve long-term cardiac function of patients, which is worthy of clinical application. Key words: Nicorandil; Acute myocardial infarction; Cardiac function; Angina pectoris; Hypersensitive troponin